• Explore /
  • Poster
  • / Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

Abstract Poster

Authors

null

Esther Pohl-Rescigno

1 Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

Esther Pohl-Rescigno , Jan Hauke , Kerstin Rhiem , Volker Möbus , Jenny Furlanetto , Carsten Denkert , Peter A. Fasching , Claus Hanusch , Hans Tesch , Nana Weber-Lassalle , Volkmar Müller , Michael Untch , Kristina Luebbe , Bianca Lederer , Christian Jackisch , Valentina Nekljudova , Rita K. Schmutzler , Sibylle Loibl , Andreas Schneeweiss , Eric Hahnen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02125344

Citation

J Clin Oncol 37, 2019 (suppl; abstr 573)

DOI

10.1200/JCO.2019.37.15_suppl.573

Abstract #

573

Poster Bd #

65

Abstract Disclosures

Similar Posters

First Author: Andreas Schneeweiss

First Author: Renske Kornalijnslijper-Altena

First Author: Sherko Kümmel

First Author: Kay T Yeung